News & Updates

The coronavirus disease 2019 (COVID-19) pandemic has caused the postponement of several sexual and reproductive health surgeries, which in turn leads to severe restrictions in the patients’ private lives and aggravates their worries about their disease, a recent study has found.

Between 2009 and 2019, Google searches regarding erectile dysfunction (ED) across the United States peak during winter, hinting at a potential seasonal dimension of ED, a recent study has found.

For men with erectile dysfunction (ED) who show a lack of response to oral phosphodiesterase type 5 inhibitors (PDE5Is), combination therapy with topical alprostadil plus PDE5Is seems favourable, producing greater improvements in sexual function without compromising safety compared with topical alprostadil alone, as shown in a study.

Patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) who have been initiated on apalutamide in a real-world setting appear to show prostate-specific antigen (PSA) response that is strong and consistent with that reported in clinical trials, as reported in a study.

The combination of olaparib and abiraterone in the first-line setting improved radiographic progression-free survival (rPFS) in patients with metastatic castration-resistant prostate cancer (mCRPC), results of the phase III PROpel trial showed.

ß3-adrenergic receptor agonists (ß3 agonists), such as mirabegron, demonstrate effectiveness and a satisfactory safety profile as adjunctive therapy in the management of paediatric neurogenic detrusor overactivity (NDO) or overactive bladder, results of a study have shown.

In men with erectile dysfunction (ED), adjuvant daily oral therapy with L-arginine and tadalafil was effective and safe in enhancing the efficacy and duration of benefits of low-intensity extracorporeal shockwave therapy (Li-ESWT), a study has shown.